CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials  by Schulz, Kenneth F. et al.
at SciVerse ScienceDirect
International Journal of Surgery 9 (2011) 672e677
GUIDELINEContents lists availableInternational Journal of Surgery
journal homepage: www.thei js .comGuideline
CONSORT 2010 statement: Updated guidelines for reporting parallel group
randomised trialsq,qq
Kenneth F. Schulz a,*, Douglas G. Altman b, David Moher c For the CONSORT Group
a Family Health International, Research Triangle Park, NC 27709, USA
bCentre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford, UK
cOttawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Department of Epidemiology and Community Medicine, University of Ottawa,
Ottawa, Canadaa r t i c l e i n f o
Article history:
Available online 13 October 2011
Keywords:
Randomized trial
Clinical trial
Controlled trial
Reporting guideline
Parallel group
CONSORTq The CONSORT statement is used worldwide to im
omised controlled trials. Kenneth Schulz and colleagu
CONSORT 2010, which updates the reporting guidel
logical evidence and accumulating experience.
qq This is an open-access article distributed unde
Commons Attribution Non-commercial License, whi
and reproduction in any medium, provided the origin
use is non-commercial and is otherwise in compliance
creativecommons.org/licenses/by-nc/2.0/ and http
ses/by-nc/2.0/legalcode.
* Corresponding author.
E-mail address: kschulz@fhi.org (K.F. Schulz).
1743-9191/$ e see front matter  2010 Schulz et al, reprinted
Attribution License (http://creativecommons.org/licenses/by/2
doi:10.1016/j.ijsu.2011.09.0041. Introduction
Randomised controlled trials, when appropriately designed,
conducted, and reported, represent the gold standard in evaluating
healthcare interventions. However, randomised trials can yield
biased results if they lack methodological rigour.1 To assess a trial
accurately, readers of a published report need complete, clear, and
transparent information on its methodology and ﬁndings. Unfor-
tunately, attempted assessments frequently fail because authors of
many trial reports neglect to provide lucid and complete descrip-
tions of that critical information.2e4
That lack of adequate reporting fuelled the development of the
original CONSORT (Consolidated Standards of Reporting Trials)
statement in 19965 and its revision ﬁve years later.6e8 While those
statements improved the reporting quality for some randomisedprove the reporting of rand-
es describe the latest version,
ine based on new methodo-
r the terms of the Creative
ch permits use, distribution,
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://creativecommons.org/licen
by Elsevier Ltd on behalf of Surgical As
.0) which permits unrestricted use, distrcontrolled trials,9,10 many trial reports still remain inadequate.2
Furthermore, new methodological evidence and additional experi-
ence has accumulated since the last revision in 2001. Consequently,
we organised a CONSORT Group meeting to update the 2001 state-
ment.6e8We introducehere the resultof thatprocess,CONSORT2010.2. Intent of CONSORT 2010
The CONSORT 2010 Statement is this paper including the 25 item
checklist in the Table 1 and the ﬂow diagram (Fig. 1). It provides
guidance for reportingall randomisedcontrolled trials, but focuses on
themost commondesign typedindividually randomised, two group,
parallel trials. Other trial designs, such as cluster randomised trials
and non-inferiority trials, require varying amounts of additional
information. CONSORT extensions for these designs,11,12 and other
CONSORT products, can be found through the CONSORT website
(www.consort-statement.org). Along with the CONSORT statement,
we have updated the explanation and elaboration article,13 which
explains the inclusionofeachchecklist item,providesmethodological
background, and gives published examples of transparent reporting.
Diligent adherence by authors to the checklist items facilitates
clarity, completeness, and transparency of reporting. Explicit
descriptions, not ambiguity or omission, best serve the interests of all
readers. Note that the CONSORT 2010 Statement does not include
recommendations for designing, conducting, and analysing trials. It
solelyaddresses the reportingofwhatwasdoneandwhatwas found.sociates Ltd. This is an open-access article distributed under the terms of the Creative Commons
ibution, and reproduction in any medium, provided the original author and source are credited.
Table 1
CONSORT 2010 checklist of information to include when reporting a randomised trial.a
Section/Topic Item No Checklist item Reported on page No
Title and abstract
1a Identiﬁcation as a randomised trial in the title
1b Structured summary of trial design, methods, results, and
conclusions (for speciﬁc guidance see CONSORT for abstracts.21,31)
Introduction
Background and objectives 2a Scientiﬁc background and explanation of rationale
2b Speciﬁc objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement
(such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufﬁcient details to allow
replication, including how and when they were actually administered
Outcomes 6a Completely deﬁned pre-speciﬁed primary and secondary outcome
measures, including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomisation
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and block size)
Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence
(such as sequentially numbered containers), describing any steps taken to conceal
the sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants,
and who assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example,
participants, care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant ﬂow (a diagram
is strongly recommended)
13a For each group, the numbers of participants who were randomly assigned,
received intended treatment, and were analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with reasons
Recruitment 14a Dates deﬁning the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis
and whether the analysis was by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the
estimated effect size and its precision (such as 95% conﬁdence interval)
17b For binary outcomes, presentation of both absolute and relative
effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and
adjusted analyses, distinguishing pre-speciﬁed from exploratory
Harms 19 All important harms or unintended effects in each group (for speciﬁc
guidance see CONSORT for harms28)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and,
if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial ﬁndings
Interpretation 22 Interpretation consistent with results, balancing beneﬁts and harms,
and considering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
a We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration13 for important clariﬁcations on all the items. If
relevant, we also recommend reading CONSORT extensions for cluster randomised trials,11 non-inferiority and equivalence trials,12 non-pharmacological treatments,32 herbal
interventions,33 and pragmatic trials.34 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.
org.
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Transparent reporting reveals deﬁciencies in research if they exist.
Thus, investigators who conduct inadequate trials, but who must
transparently report, should not be able to pass through the publi-
cation process without revelation of their trial’s inadequacies. That
emerging reality should provide impetus to improved trial design
and conduct in the future, a secondary indirect goal of our work.
Moreover, CONSORT can help researchers in designing their trial.3. Background to CONSORT
Efforts to improve the reporting of randomised controlled trials
accelerated in the mid-1990s, spurred partly by methodological
research. Researchers had shown for many years that authors re-
ported such trials poorly, and empirical evidence began to accumu-
late that some poorly conducted or poorly reported aspects of trials
were associated with bias.14 Two initiatives aimed at developing
Fig. 1. Flow diagram of the progress through the phases of a parallel randomised trial of two groups (that is, enrolment, intervention allocation, follow-up, and data analysis).
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Rennie organising the ﬁrst CONSORT statement in 1996.5 Further
methodological research on similar topics reinforced earlier ﬁnd-
ings15 and fed into the revision of 2001.6e8 Subsequently, the
expanding body of methodological research informed the reﬁne-
ment of CONSORT 2010. More than 700 studies comprise the
CONSORT database (located on the CONSORT website), which
provides the empirical evidence to underpin the CONSORT initiative.
Indeed, CONSORT Group members continually monitor the liter-
ature. Information gleaned from these efforts provides an evidence
base on which to update the CONSORT statement. We add, drop, or
modify itemsbasedonthatevidenceand the recommendationsof the
CONSORT Group, an international and eclectic group of clinical tria-
lists, statisticians, epidemiologists, and biomedical editors. The
CONSORT Executive (KFS, DGA, DM) strives for a balance of estab-
lished and emerging researchers. The membership of the group is
dynamic. As our work expands in response to emerging projects and
needed expertise, we invite new members to contribute. As such,
CONSORT continually assimilates new ideas and perspectives. That
process informs the continually evolving CONSORT statement.
Over time, CONSORT has garnered much support. More than 400
journals, published around the world and in many languages, have
explicitly supported the CONSORT statement. Many other healthcare
journals support itwithoutourknowledge.Moreover, thousandsmore
have implicitly supported it with the endorsement of the CONSORT
statement by the International Committee of Medical Journal Editors
(www.icmje.org). Other prominent editorial groups, the Council of
ScienceEditors and theWorldAssociation ofMedical Editors, ofﬁcially
support CONSORT. That support seems warranted: when used by
authors and journals, CONSORT seems to improve reporting.94. Development of CONSORT 2010
Thirty one members of the CONSORT 2010 Group met in Mon-
tebello, Canada, in January 2007 to update the 2001 CONSORT
statement. In addition to the accumulating evidence relating to
existing checklist items, several new issues had come to prominence
since 2001. Some participants were given primary responsibility for
aggregating and synthesising the relevant evidence on a particular
checklist item of interest. Based on that evidence, the group deliber-
ated the value of each item. As in prior CONSORT versions, we keptonly those items deemed absolutely fundamental to reporting
a randomisedcontrolled trial.Moreover, an itemmaybe fundamental
to a trial but not included, such as approval by an institutional ethical
review board, because funding bodies strictly enforce ethical review
andmedical journals usually address reporting ethical review in their
instructions for authors. Other items may seem desirable, such as
reporting on whether on-site monitoring was done, but a lack of
empirical evidence or any consensus on their value cautions against
inclusion at this point. The CONSORT 2010 Statement thus addresses
the minimum criteria, although that should not deter authors from
including other information if they consider it important.
After the meeting, the CONSORT Executive convened teleconfer-
ences and meetings to revise the checklist. After seven major itera-
tions, a revised checklist was distributed to the larger group for
feedback. With that feedback, the executive met twice in person to
consider all the comments and to produce a penultimate version.
That served as the basis for writing theﬁrst draft of this paper, which
was thendistributed to the group for feedback. After consideration of
their comments, the executive ﬁnalised the statement.
The CONSORT Executive then drafted an updated explanation
and elaboration manuscript, with assistance from other members
of the larger group. The substance of the 2007 CONSORT meeting
provided the material for the update. The updated explanation and
elaboration manuscript was distributed to the entire group for
additions, deletions, and changes. That ﬁnal iterative process
converged to the CONSORT 2010 Explanation and Elaboration.135. Changes in CONSORT 2010
The revision process resulted in evolutionary, not revolutionary,
changes to the checklist (Table 1), and the ﬂow diagram was not
modiﬁed except for one word (Fig. 1). Moreover, because other
reporting guidelines augmenting the checklist refer to item
numbers, we kept the existing items under their previous item
numbers except for some renumbering of items 2 to 5. We added
additional items either as a sub-item under an existing item, an
entirely new item number at the end of the checklist, or (with item
3) an interjected item into a renumbered segment. We have sum-
marised the noteworthy general changes in tbox 1 and speciﬁc
changes in Box 2. The CONSORT website contains a side by side
comparison of the 2001 and 2010 versions.
Box 1. Noteworthy general changes in CONSORT 2010
Statement.
 We simplified and clarified the wording, such as in
items 1, 8, 10, 13, 15, 16, 18, 19, and 21
 We improved consistency of style across the items by
removing the imperative verbs that were in the 2001
version
 We enhanced specificity of appraisal by breaking some
items into sub-items. Many journals expect authors to
complete a CONSORT checklist indicating where in the
manuscript the items have been addressed. Experience
with the checklist noted pragmatic difficulties when an
item comprised multiple elements. For example, item 4
addresses eligibility of participants and the settings and
locations of data collection. With the 2001 version, an
author could provide a page number for that item on
the checklist, but might have reported only eligibility in
the paper, for example, and not reported the settings
and locations. CONSORT 2010 relieves obfuscations
and forces authors to provide page numbers in the
checklist for both eligibility and settings
Box 2. Noteworthy specific changes in CONSORT 2010
Statement.
 Item 1b (title and abstract)dWe added a sub-item on
providing a structured summary of trial design,
methods, results, and conclusions and referenced the
CONSORT for abstracts article21
 Item 2b (introduction)dWe added a new sub-item
(formerly item 5 in CONSORT 2001) on “Specific
objectives or hypotheses”
 Item 3a (trial design)dWe added a new item including
this sub-item to clarify the basic trial design (such as
parallel group, crossover, cluster) and the allocation ratio
 Item 3b (trial design)dWe added a new sub-item that
addresses any important changes to methods after trial
commencement, with a discussion of reasons
 Item 4 (participants)dFormerly item 3 in CONSORT
2001
 Item 5 (interventions)dFormerly item 4 in CONSORT
2001. We encouraged greater specificity by stating that
descriptions of interventions should include “sufficient
details to allow replication”3
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We developed CONSORT 2010 to assist authors in writing
reports of randomised controlled trials, editors and peer reviewers
in reviewing manuscripts for publication, and readers in critically
appraising published articles. The CONSORT 2010 Explanation and
Elaboration provides elucidation and context to the checklist items.
We strongly recommend using the explanation and elaboration in
conjunction with the checklist to foster complete, clear, and
transparent reporting and aid appraisal of published trial reports.
CONSORT 2010 focuses predominantly on the two group,
parallel randomised controlled trial, which accounts for over half of
trials in the literature.2 Most of the items from the CONSORT 2010
Statement, however, pertain to all types of randomised trials.
Nevertheless, some types of trials or trial situations dictate the need
for additional information in the trial report. When in doubt,
authors, editors, and readers should consult the CONSORT website
for any CONSORT extensions, expansions (ampliﬁcations), imple-
mentations, or other guidance that may be relevant.
The evidence based approach we have used for CONSORT also
served as amodel for development of other reporting guidelines, such
as for reporting systematic reviews and meta-analyses of studies
evaluating interventions,16 diagnostic studies,17 and observational
studies.18 The explicit goal of all these initiatives is to improve report-
ing. The Enhancing the Quality and Transparency of Health Research
(EQUATOR) Network will facilitate development of reporting guide-
lines and help disseminate the guidelines: www.equator-network.org
provides information on all reporting guidelines in health research.
With CONSORT 2010, we again intentionally declined to
produce a rigid structure for the reporting of randomised trials.
Indeed, SORT19 tried a rigid format, and it failed in a pilot run with
an editor and authors.20 Consequently, the format of articles should
abide by journal style, editorial directions, the traditions of the
research ﬁeld addressed, and, where possible, author preferences.
We do not wish to standardise the structure of reporting. Authors
should simply address checklist items somewhere in the article,
with ample detail and lucidity. That stated, we think that manu-
scripts beneﬁt from frequent subheadings within the major
sections, especially the methods and results sections.
CONSORT urges completeness, clarity, and transparency of report-
ing,which simply reﬂects the actual trial design and conduct.However,
as a potential drawback, a reporting guideline might encourage some
authors to reportﬁctitiously the informationsuggestedby theguidance
rather than what was actually done. Authors, peer reviewers, and
editors should vigilantly guard against that potential drawback and
refer, forexample, totrialprotocols, to informationontrial registers, and
to regulatoryagencywebsites.Moreover, theCONSORT2010Statement
does not include recommendations for designing and conducting
randomisedtrials.The itemsshouldelicit clearpronouncementsofhow
and what the authors did, but do not contain any judgments on how
and what the authors should have done. Thus, CONSORT 2010 is not
intended as an instrument to evaluate the quality of a trial. Nor is it
appropriate to use the checklist to construct a “quality score.”
Nevertheless, we suggest that researchers begin trials with their
end publication in mind. Poor reporting allows authors, inten-
tionally or inadvertently, to escape scrutiny of any weak aspects of
their trials. However, with wide adoption of CONSORT by journals
and editorial groups, most authors should have to report trans-
parently all important aspects of their trial. The ensuing scrutiny
rewards well conducted trials and penalises poorly conducted
trials. Thus, investigators should understand the CONSORT 2010
reporting guidelines before starting a trial as a further incentive to
design and conduct their trials according to rigorous standards.
CONSORT 2010 supplants the prior version published in 2001.
Any support for the earlier version accumulated from journals oreditorial groups will automatically extend to this newer version,
unless speciﬁcally requested otherwise. Journals that do not
currently support CONSORT may do so by registering on the
CONSORTwebsite. If a journal supports or endorses CONSORT 2010,
it should cite one of the original versions of CONSORT 2010, the
CONSORT 2010 Explanation and Elaboration, and the CONSORT
website in their “Instructions to authors.” We suggest that authors
who wish to cite CONSORT should cite this or another of the orig-
inal journal versions of CONSORT 2010 Statement, and, if appro-
priate, the CONSORT 2010 Explanation and Elaboration.13 All
CONSORT material can be accessed through the original publishing
journals or the CONSORTwebsite. Groups or individuals who desire
to translate the CONSORT 2010 Statement into other languages
should ﬁrst consult the CONSORT policy statement on the website.
We emphasise that CONSORT 2010 represents an evolving
guideline. It requires perpetual reappraisal and, if necessary,
modiﬁcations. In the future we will further revise the CONSORT
material considering comments, criticisms, experiences, and
accumulating new evidence. We invite readers to submit recom-
mendations via the CONSORT website.
 Item 6 (outcomes)dWeadded a sub-itemon identifying
any changes to the primary and secondary outcome
(endpoint) measures after the trial started. This fol-
lowed from empirical evidence that authors frequently
provide analyses of outcomes in their published papers
that were not the pre-specified primary and secondary
outcomes in their protocols, while ignoring their pre-
specified outcomes (that is, selective outcome report-
ing).4,22 We eliminated text on any methods used to
enhance the quality of measurements
 Item 9 (allocation concealment mechanism)dWe
reworded this to include mechanism in both the report
topic and the descriptor to reinforce that authors should
report the actual steps taken to ensure allocation
concealment rather than simply report imprecise,
perhaps banal, assurances of concealment
 Item 11 (blinding)dWe added the specification of how
blinding was done and, if relevant, a description of the
similarity of interventions and procedures. We also
eliminated text on “how the success of blinding (mask-
ing) was assessed” because of a lack of empirical
evidence supporting the practice as well as theoretical
concerns about the validity of any such assessment.23,24
 Item 12a (statistical methods)dWe added that statis-
tical methods should also be provided for analysis of
secondary outcomes
 Sub-item 14b (recruitment)dBased on empirical
research, we added a sub-item on “Why the trial ended
or was stopped”25
 Item 15 (baseline data)dWe specified “A table” to
clarify that baseline and clinical characteristics of each
group are most clearly expressed in a table
 Item 16 (numbers analysed)dWe replaced mention of
“intention to treat” analysis, a widely misused term, by
a more explicit request for information about retaining
participants in their original assigned groups26
 Sub-item 17b (outcomes and estimation)dFor appro-
priate clinical interpretability, prevailing experience
suggested the addition of “For binary outcomes,
presentation of both relative and absolute effect sizes is
recommended”27
 Item 19 (harms)dWe included a reference to the
CONSORT paper on harms28
 Item 20 (limitations)dWe changed the topic from
“Interpretation” and supplanted the prior text with
a sentence focusing on the reporting of sources of
potential bias and imprecision
 Item 22 (interpretation)dWe changed the topic from
“Overall evidence.” Indeed, we understand that authors
should be allowed leeway for interpretation under this
nebulous heading. However, the CONSORT Group
expressed concerns that conclusions in papers
frequently misrepresented the actual analytical results
and that harms were ignored or marginalised. There-
fore, we changed the checklist item to include the
concepts of results matching interpretations and of
benefits being balanced with harms
 Item 23 (registration)dWe added a new item on trial
registration. Empirical evidence supports the need for
trial registration, and recent requirements by journal
editors have fostered compliance29
 Item 24 (protocol)dWe added a new item on avail-
ability of the trial protocol. Empirical evidence suggests
that authors often ignore, in the conduct and reporting
of their trial, what they stated in the protocol.4,22 Hence,
availability of the protocol can instigate adherence to
the protocol before publication and facilitate assess-
ment of adherence after publication
 Item 25 (funding)dWe added a new item on funding.
Empirical evidence points toward funding source some-
timesbeingassociatedwithestimatedtreatmenteffects30
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